Advanced Lipid Technologies® (ALT®): A Proven Formulation Platform to Enhance the Bioavailability of Lipophilic Compounds
Figure 3
Advanced Lipid Technologies® (ALT®) significantly improves omega-3 fatty acid absorption. (a) Phase I, Single-Dose, Open-Label, Randomized, Three-Way Crossover Study of Food Effect on the Pharmacokinetics of Omega-3-Acid Ethyl Esters in Healthy Subjects was performed to quantify the BA of EPA + DHA after treatment with 1530 mg EPA EE+ DHA EE in fasted and high or low fat feeding conditions. Mean ± standard error of the total EPA + DHA concentration-time profiles after a single oral dose of SC401 (1530 mg of DHA EE + EPA EE with ALT®) in fasted, low fat or high fat diet conditions. (b) Phase I, Single-Dose, Open-Label, Randomized, Two-Way Crossover Study, the Relative Bioavailability of 1530 mg of EPA EE + DHA EE with ALT® vs. 3600 mg of EPA EE + DHA EE, was compared under low fat fed conditions. Mean ± standard deviation of total lipid EPA + DHA concentration-time profiles after a single oral dose of SC401 (1530 mg of DHA-EE + EPA EE) or Lovaza® (3600 mg of DHA EE + EPA EE) in low-fat feeding conditions (N = 23). DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid.